Are Central Institutional Review Boards the Solution? The National Heart, Lung, and Blood Institute Working Group’s Report on Optimizing the IRB Process
- 1 December 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 87 (12) , 1710-1714
Abstract
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened a working group in June 2011 to examine alternative institutional review board (IRB) models. The working group was held in response to proposed changes in the regulations for government-supported research and the proliferation of multicenter clinical trials where multiple individual reviews may be inefficient. Group members included experts in heart, lung, and blood research, research oversight, bioethics, health economics, regulations, and information technology (IT). The group discussed alternative IRB models, ethical concerns, metrics for evaluating IRBs, IT needs, and economic considerations. Participants noted research gaps in IRB best practices and in metrics. The group arrived at recommendations for process changes, such as defining specific IRB performance requirements in funding announcements, requiring funded researchers to use more efficient alternative IRB models, and developing IT systems to facilitate information sharing and collaboration among IRBs. Despite the success of the National Cancer Institute’s central IRB (CIRB), the working group, concerned about the creation costs and unknown cost-efficiency of a new CIRB, and about the risk of shifting the burden of dealing with multiple IRBs from sponsors to research institutions, did not recommend the creation of an NHLBI-funded CIRB.Keywords
This publication has 14 references indexed in Scilit:
- The Paradoxical Problem with Multiple-IRB ReviewNew England Journal of Medicine, 2010
- Do IRBs Protect Human Research Participants?JAMA, 2010
- Costs and Benefits of the National Cancer Institute Central Institutional Review BoardJournal of Clinical Oncology, 2010
- The Dysregulation of Human Subjects ResearchJAMA, 2007
- Financial Relationships between Institutional Review Board Members and IndustryNew England Journal of Medicine, 2006
- Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical TrialsJournal of Clinical Oncology, 2006
- The Cost of Institutional Review Boards in Academic Medical CentersNew England Journal of Medicine, 2005
- Problematic Variation in Local Institutional Review of a Multicenter Genetic Epidemiology StudyJAMA, 2003
- Variability in Institutional Review Board Assessment of Minimal-risk ResearchAcademic Emergency Medicine, 2002
- A Central Institutional Review Board for Multi-Institutional TrialsNew England Journal of Medicine, 2002